# Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients

> **NCT02897596** · PHASE3 · UNKNOWN · sponsor: **Fundacion Clinic per a la Recerca Biomédica** · enrollment: 62 (estimated)

## Conditions studied

- Hepatitis C
- HIV

## Interventions

- **DRUG:** Grazoprevir 100 mg/d 8 weeks
- **DRUG:** Elbasvir 50 mg/d 8 weeks
- **DRUG:** Grazoprevir 100 mg/d 12 weeks
- **DRUG:** Elbasvir 50 mg/d 12 weeks

## Key facts

- **NCT ID:** NCT02897596
- **Lead sponsor:** Fundacion Clinic per a la Recerca Biomédica
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-28
- **Primary completion:** 2019-04-28
- **Final completion:** 2019-10-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02897596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02897596, "Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02897596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*